Atomo Diagnostics Limited announced that the Atomo COVID-19 Antigen Test (Nasal, Nasopharyngeal, or Oropharyngeal swab) has been authorised by the New Zealand Ministry of Health under the New Zealand COVID-19 Public Health Response 2020 (Point of Care) Order (the Order). The authorisation covers professional or self-test use and means authorised persons or classes of persons such as NZ District Health Board hospitals, Government agencies, the healthcare workforce, New Zealand-based businesses and pharmacies are all permitted to supply, distribute, and sell the COVID-19 Antigen Test in New Zealand to other authorized persons or classes of persons, and to also use the Test. Atomo announced on 5 October 2021 that it had renegotiated its supply agreement with US manufacturer Access Bio providing the right, but not the obligation, for Atomo to purchase at a fixed price per unit up to 20 million COVID-19 rapid antigen tests (Atomo branded) during Current year 2022 for sale in Australia and New Zealand.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.028 AUD | -3.45% |
|
0.00% | +27.27% |
Jun. 12 | Atomo Diagnostics Advances Australia-Wide HIV Self-Test Kit Rollout; Shares Rise 4% | MT |
May. 16 | Easing US Inflation Boosts Australian Shares to Six-Week High | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+27.27% | 12.37M | |
+4.98% | 217B | |
+7.44% | 191B | |
+28.22% | 154B | |
+33.19% | 112B | |
+1.22% | 62.75B | |
+16.51% | 53.34B | |
+1.45% | 48.88B | |
-4.53% | 39.36B | |
+2.74% | 35.73B |
- Stock Market
- Equities
- AT1 Stock
- News Atomo Diagnostics Limited
- Atomo Diagnostics Limited Receives Approval for its Covid-19 Antigen Test in NZ